



ctos[®]

2023

**ANNUAL
MEETING**

DUBLIN, IRELAND
NOVEMBER 1 - 4

SCHEDULE AT A GLANCE

THANK YOU

The Connective Tissue Oncology Society
greatly appreciates your support of the 2023 Annual Meeting.

PLATINUM SPONSOR



SILVER SPONSORS



BRONZE SPONSORS



SPECIAL THANKS TO FRIENDS OF CTOS:

ADAPTIMMUNE	ADVENCHEN LABORATORIES	AGENUS INC.
ASTEX PHARMACEUTICALS	AVACTA LIFE SCIENCES	BLUEPRINT MEDICINES
C4 THERAPEUTICS	PTC THERAPEUTICS	TRACON PHARMA



ctos[®]



Dear Colleagues,

We invite you to join us for the 2023 CTOS Annual Meeting which will be held November 1-4 at the Convention Centre Dublin.

It is our pleasure to welcome keynote speakers Rick Haas, MD who will give the Nina Axelrad Lecture, and Katherine Janeway, MD, who will give the Herman Suit Lecture. Their presentations should not be missed!

Sarcoma of the year will be the Small Round Blue Cell Sarcomas, including Ewing, Non-ETS rearranged, the CIC-rearranged, and BCOR tumor family. Amongst a whole slew (or "slua", if you prefer the original Gaelic version) of Special Sessions are included ones focussing on : "Sarcoma Biology and 'Omics", "Improving Sarcoma Care Globally: Access, Equity, Advocacy, and Policy" "Innovations and Controversies in Radiation Oncology" and "Novel Diagnostics and Bioinformatics". We are also introducing a new session during the 2023 CTOS Annual Meeting on Operative and Procedural Videos on Sarcoma Management. This session will take place on Wednesday, November 1 from 2:00 PM to 3:00 PM. Additionally, in order to generate more live intellectual exchange between investigators, we are pleased to have 'upgraded' "Trials in Progress (TIP)" to a distinct abstract category its own dedicated session. For the first time, investigators can now pitch their ongoing projects as a TIP oral presentation to the broader CTOS audience. We hope this will increase interest and support from the entire CTOS community, generating a greater global footprint for sarcoma therapeutic advancement.

The morning Mentorship sessions will feature again this year with topics galore (or "go leor", if you want the original Gaelic version of the term!) "The Debate" as a new presentation mode proved a popular hit at CTOS in Vancouver and will be featured again this year, indeed in duplicate! There will be a welcome reception with traditional Irish entertainment, a poster reception, and the Gala dinner will be in the fabulous location of the Guinness Storehouse, where you will be treated to some more great Irish music, festivities, food, and of course a drop of the black stuff.

CTOS is committed to fostering all aspects of sarcoma research and treatment. We welcome physicians working in all disciplines that deal with sarcoma care, including radiology (diagnostic and interventional), pathology, surgery (oncologic, orthopedic, reconstructive, neuro-), medical oncology, pediatric oncology, and radiation oncology. We also welcome translational and basic science researchers, survivorship care providers, nursing staff, patients, and patient advocates to join us as well to contribute to the scientific program.

Looking forward to seeing you soon in Dublin!

Rebecca Gladdy, MD, PhD, Program Co-Chair
Ashleigh Guadagnolo, MD, MPH, Program Co-Chair
Herbert Loong, MBBS, FRCP, Program Co-Chair
Maureen O'Sullivan, MBBCh, MD, Program Co-Chair

Carol Swallow, MD, PhD, CTOS 2023 President



Fyarro[®]

sirolimus protein-bound particles
for injectable suspension (albumin-bound)

DIVE DEEP INTO THE DATA

Learn more at

FYARROHCP.com

FYARRO is only approved in the U.S. and not authorized for sale outside of the U.S. Intended for U.S.-based healthcare professionals.



FYARRO[®] is a registered trademark of Aadi Bioscience, Inc.
© 2023 Aadi Bioscience, Inc. All rights reserved. US-FYA-2300102 9/23



ctos[®]

2023 BOARD OF DIRECTORS

Carol Swallow, MD, *President*

Damon Reed, MD, *Vice President*

Silvia Stacchiotti, MD, *Secretary*

Robin Jones, MD, *Treasurer*

William Tap, MD, *Immediate Past President*

Margaret von Mehren, MD (2021-2023)

Bernd Kasper, MD, PhD (2021-2023)

E. Alejandro Sweet-Cordero, MD (2021-2023)

Inga-Marie Schaefer, MD (2022-2024)

Herbert Loong, MD (2022-2024)

Chandrajit Raut, MD (2022-2024)

Noah Federman, MD (2022-2024)

Sandra D'Angelo, MD (2023-2025)

Rebecca Gladdy, MD, PhD (2023-2025)

Nadia Hindi, MD (2023-2025)

Torsten Nielsen, MD, PhD (2023-2025)

Barbara Rapp, *Executive Director*



RETHINK DESMOID TUMORS

Don't underestimate these unpredictable tumors and their “tendrill-like” growths¹

- Desmoid tumors can be locally invasive and painful, with “**tendrill-like**” growths that can threaten vital structures and compromise patients’ function and quality of life²⁻⁴
- Approximately **30% to 40%** of desmoid tumors are initially misdiagnosed due to their rarity and histologic mimics¹
- In most cases, **surgery is no longer the recommended first-line treatment approach** for desmoid tumors^{1,5}

A diagnosis can raise more questions for patients than answers. SpringWorks Therapeutics is committed to helping you provide resources and information for your patients with desmoid tumors.

References: **1.** Kasper B, Baumgarten C, Garcia J, et al. Desmoid Working Group. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). *Ann Oncol.* 2017;28(10):2399-2408. **2.** Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. *Curr Opin Oncol.* 2017;29(4):268-274. **3.** Baranov E, Hornick JL. Soft tissue special issue: fibroblastic and myofibroblastic neoplasms of the head and neck. *Head Neck Pathol.* 2020;14(1):43-58. **4.** Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? *Support Care Cancer.* 2019;27(3):965-980. **5.** Gronchi A, et al. Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. *Eur J Cancer.* 2020;127:96-107.





ctos®

2023 ANNUAL MEETING

NOVEMBER 1 – 14, 2023

DUBLIN, IRELAND


2023 ANNUAL MEETING SCHEDULE AT A GLANCE

WEDNESDAY, NOVEMBER 1, 2023

7:00 AM – 5:30 PM	Registration	Lobby
8:00 AM – 12:00 PM	TARPSWG	Wicklow Hall 2
1:00 PM – 3:00 PM	Ultra-Rare Sarcoma Meeting	Wicklow Hall 2
2:00 PM – 3:15 PM	Operative and Procedural Video Session 	Liffey Hall 1, Level 1
3:30 PM – 5:30 PM	Festschrift for Chris Fletcher	The Auditorium
5:30 PM – 7:00 PM	Welcome Reception	3rd Floor Foyer

THURSDAY, NOVEMBER 2, 2023

6:30 AM – 6:00 PM	Registration	Lobby
7:15 AM – 8:15 AM	Sunrise Mentorship Session	The Forum
8:30 AM – 5:00 PM	Patient Advocacy Lounge (Hosted by SPAGN)	Liffey Hall 2
8:30 AM – 6:00 PM	Nursing and Allied Health Professionals Meeting	Wicklow Hall 2
8:30 AM – 9:00 AM	Opening Ceremony	The Auditorium
9:00 AM – 10:00 AM	SESSION 1: IMPROVING SARCOMA CARE GLOBALLY: ACCESS, EQUITY, ADVOCACY, AND POLICY	The Auditorium
10:00 AM – 10:30 AM	DEBATE 1: Sarcoma Surgeries Should Only Be Performed In Qualified Centers with Adequate Sarcoma Surgical Volume Moderator: Mark A. Dickson, MD Presenters: Sylvie Bonvalot, MD, PhD Jeffery Farma, MD, FACS	The Auditorium
10:30 AM – 11:00 AM	Coffee Break	The Liffey
11:00 AM – 12:30 PM	SESSION 2: SARCOMA BIOLOGY AND 'OMICS	The Auditorium
12:30 PM – 1:30 PM	Lunch	The Forum



INBRX-109: A POTENTIAL NEW TREATMENT FOR CHONDROSARCOMA

***NOW ENROLLING: A REGISTRATION-ENABLING STUDY
IN CONVENTIONAL CHONDROSARCOMA***



SCAN TO LEARN MORE ABOUT THIS CLINICAL TRIAL

INHIBRX

THURSDAY, NOVEMBER 2, 2023, CONTINUED

1:30 PM – 2:00 PM	NINA AXELRAD LECTURE "Radiotherapy Dose and Fraction Size: A Sarcoma Patient's Best Friends" – Rick Haas, MD, PhD	The Auditorium
2:00 PM – 3:00 PM	SESSION 3: RADIATION ONCOLOGY: UPDATES, INNOVATIONS, & CONTROVERSIES	The Auditorium
3:30 PM – 4:00 PM	Coffee Break	The Liffey
4:00 PM – 5:30 PM	SESSION 4: MEDICAL AND PEDIATRIC ONCOLOGY TRIALS	The Auditorium
5:30 PM – 6:30 PM	POSTER RECEPTION	The Liffey

FRIDAY, NOVEMBER 3, 2023

7:00 AM – 6:00 PM	Registration	Lobby
7:30 AM – 8:30 AM	Executive Committee Meeting	Liffey Meeting Room 1
7:45 AM – 8:45 AM	Sunrise Mentorship Session	The Forum
8:30 AM – 5:00 PM	Patient Advocacy Lounge (Hosted by SPAGN)	Liffey Hall 2
9:00 AM – 10:00 AM	SESSION 5: IMMUNOLOGY AND IMMUNOTHERAPY	The Auditorium
10:00 AM – 11:00 AM	SESSION 6: SARCOMA OF THE YEAR: SMALL ROUND BLUE CELL TUMOR	The Auditorium
11:00 AM – 11:30 AM	Coffee Break	The Liffey
11:30 AM – 12:30 PM	SESSION 7: NOVEL DIAGNOSTICS AND BIOINFOMATICS	The Auditorium
12:30 PM – 1:00 PM	DEBATE 2: Drugs That Have Not Received Regulatory Approvals In Sarcomas Should Not Be Used to Treat Sarcoma Patients Except On a Clinical Trial Moderator: Mark A. Dickson, MD Presenters: Robin Jones, MD Herbert Loong, MBBS, FRCP	The Auditorium
1:00 PM – 2:00 PM	Board of Directors Meeting	Liffey Meeting Room 2
1:00 PM – 2:00 PM	Lunch	The Forum
2:00 PM – 2:30 PM	HERMAN SUIT LECTURE "Why I Sequence the Cancer Genome of All Pediatric and AYA Sarcomas" – Katherine A. Janeway, MD	The Auditorium
2:30 PM – 4:00 PM	SESSION 8: ADOLESCENT AND YOUNG ADULT SARCOMAS	The Auditorium
4:00 PM – 4:30 PM	Coffee Break	The Liffey
4:30 PM – 6:00 PM	SESSION 9: ORTHOPEDIC & RECONSTRUCTIVE SURGERY	The Auditorium
7:30 PM	GALA at the Guinness Storehouse	Guinness Storehouse



QINLOCK[®]
(ripretinib) 50 mg tablets



FOR ADVANCED **GIST** PATIENTS
TREATED WITH ≥ 3 PRIOR TKIs

BREAK THROUGH RESISTANCE

Approved for patients regardless of mutation, including¹:

✓ **KIT** ✓ **PDGFR α** ✓ **WILD TYPE**

QINLOCK may cause photosensitivity reactions. Advise patients to limit direct ultraviolet exposure during treatment with QINLOCK and for at least 1 week after discontinuation of treatment.

QINLOCK can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose.

The most common adverse reactions (>35%) include alopecia, fatigue, nausea, and abdominal pain.

The safety and effectiveness of QINLOCK in pediatric patients have not been established.

Administer strong CYP3A inhibitors with caution. Avoid concomitant use with strong and moderate CYP3A inducers. If a moderate CYP3A inducer cannot be avoided, increase QINLOCK dosing frequency from the recommended dose of 150 mg once daily to 150 mg twice daily during the co-administration period.

Please see additional complete Safety Information and full Prescribing Information, including Patient Information at QINLOCKHCP.com.

To report SUSPECTED ADVERSE REACTIONS, contact Deciphera Pharmaceuticals, LLC, at 1-888-724-3274 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Reference: 1. Qinlock [package insert]. Waltham, MA: Deciphera Pharmaceuticals, Inc; 2022.

INDICATION

QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

SELECT SAFETY INFORMATION

Serious adverse reactions occurred in 31% of patients who received QINLOCK. Serious adverse reactions that occurred in >2% of patients were abdominal pain (4.7%), anemia (3.5%), nausea (2.4%), and vomiting (2.4%).

Palmar-plantar erythrodysesthesia syndrome (PPES), new primary cutaneous malignancies, hypertension, and cardiac dysfunction were reported in patients receiving QINLOCK in the INVICTUS trial.

QINLOCK has the potential to adversely affect wound healing. Withhold QINLOCK for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of QINLOCK after resolution of wound healing complications has not been established.

GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; PDGFR α =platelet derived growth factor receptor α ; TKI=tyrosine kinase inhibitor.

© 2022 Deciphera Pharmaceuticals. The QINLOCK[®] word mark and logo are registered trademarks of Deciphera Pharmaceuticals, LLC. Deciphera and Deciphera Pharmaceuticals are trademarks of Deciphera Pharmaceuticals, LLC. All rights reserved. DCPH-P00807 10/22

SATURDAY, NOVEMBER 4, 2023

8:00 AM – 5:00 PM	Registration	Lobby
8:30 AM – 5:00 PM	Patient Advocacy Lounge (Hosted by SPAGN)	Liffey Hall 2
9:00 AM – 10:00 AM	SESSION 10: TRIALS IN PROGRESS	The Auditorium
10:00 AM – 11:00 AM	SESSION 11: BONE SARCOMAS	The Auditorium
11:00 AM – 11:30 AM	Coffee Break	The Liffey
11:30 AM – 1:00 PM	SESSION 12: PRECLINICAL MODELS AND TRANSLATIONAL RESEARCH	The Auditorium
1:00 PM – 2:00 PM	Lunch	The Forum
1:00 PM – 2:00 PM	SPAGN Mentee Lunch	Liffey Hall 2
2:00 PM – 3:00 PM	SESSION 13: RETROPERITONEAL AND ABDOMINAL SARCOMAS	The Auditorium
3:00 PM – 4:00 PM	SESSION 14: GIST	The Auditorium
4:00 PM – 4:30 PM	Coffee Break	The Liffey
4:30 PM – 6:00 PM	AWARDS SESSION: Young Investigator Award Winners Liddy Shriver Early Research Award Winner Basic Science Sarcoma Research Award Winners	
6:00 PM – 6:30 PM	CTOS Business Meeting	The Auditorium
6:30 PM	Adjourn	

The logo for Abbisko features a large, stylized letter 'A' in a dark red color. To its right, the word 'Abbisko' is written in a blue, serif font. A small cluster of red dots is positioned above the 'i' in 'Abbisko'.

WE DISCOVER AND DEVELOP NOVEL AND
DIFFERENTIATED THERAPIES IN CANCER AND BEYOND

**ADDRESS UNMET MEDICAL NEEDS FOR
PATIENTS IN CHINA AND GLOBALLY**

Founded in 2016, we have established a robust in-house R&D engine underpinned by an outstanding discovery team and a multi-dimensional discovery platform. We have strategically designed and developed a rich pipeline of 10+ small molecule programs focused on oncology.

<https://www.abbisko.com/>

SPAGN's Global Community 2023

60+ Member Groups from all Parts of the World



Sarcoma
Patient Advocacy
Global Network

Working together, making a difference

Logos included in the collage:

- AEAS: Asociación Española de Afectados por Sarcomas
- LeiomyoSarcoma: SUPPORT & DIRECT RESEARCH FOUNDATION
- Suomen Syöpäpotilaat - Cancerpatienterna i Finland ry
- GIST SUPPORT ÖSTERREICH: Verein zur Unterstützung von Betroffenen
- genCBirder
- DESMOID FOUNDATION
- Together we share and learn
- SARKOMFÖRENINGEN
- SMARCB1 e.V.
- Patiëntenplatform Sarcomen
- SARCOMA STOWARZYSZENIE POMOCY CHOROBYM NA MIĘSIAKI
- SARCOMA COALITION: We are here for you.
- synovial sarcoma research foundation
- CHONDROSARCOMA FOUNDATION
- sos desmoid
- SARCOMA SFA: Foundation of America, finding the cure in our time
- HENZO KENYA
- National LEIOMYOSARCOMA Foundation: nlmf.org
- GIST-ERS
- SarcomaUK: The bone & soft tissue cancer charity
- SOS DESMOÏDE
- CUM CURA: met zorg
- Sarcoma Cancer Ireland
- A.I.G. Associazione Italiana GIST ONLUS
- SACHIN SARCOMA SOCIETY
- TRUST PAOLA GONZATO Rete Sarcoma ONLUS
- glist canceruk
- Sarkomer: Støtteleforening for alle berørt af sarcoma
- SARKOME DEUTSCHE SARKOM STIFTUNG
- MIB AGENTS
- TOGETHER FIGHTING SARCOMA
- BONE CANCER RESEARCH TRUST: UNTIL THERE'S A CURE
- V Care: Support and Hope for those touched by cancer
- RARE CANCER REHE CHARITY (UK)
- IN CORSA PER LA VITA!
- CAMPAINING FOR CANCER
- GIST & STS Alliance for patients - Europe
- sock it to Sarcoma!
- GIST
- CHORDOMA FOUNDATION
- SWISS sarcoma: VON BETROFFENEN FÜR BETROFFENE
- sarcoma alliance
- GIST.ch: GIST-GROUPE SCHWEIZ / GROUPE GIST SUISSE
- The Life Raft GROUP
- PAWS - GIST: Improving treatment & finding a cure for rare GIST cancer in young people
- Érintettek Egyesület
- Info Sarcomes: Ensemble contre les Sarcomes
- opv: Associazione Orchestra per la vita ONLUS
- myrovlytis XXXX trust
- The George Pantziarka TP53 Trust: Helping families with Li Fraumeni Syndrome and related conditions
- GIST Organization
- SARCOMA STRONG: UNITE THE FIGHT
- Fundación MARI PAZ JIMÉNEZ CASADO

We are *inspired* by the sea, *driven* by science, and *motivated* by patients with serious diseases to improve their lives. We intend to continue to be the *world leader* in marine medicinal discovery, development and innovation.

pharmamar.com



ctos[®] |

Bringing together the
world's sarcoma specialists[®]

The Connective Tissue Oncology Society

For more information,
Please visit the CTOS website:
www.ctos.org

P.O. Box 320574 Alexandria, VA 22320
Phone: 301/502-7371 e-mail: ctos@ctos.org

Barbara Rapp, Executive Director



ctos[®]

SAVE THE DATE

November 13 - 16, 2024
Manchester Grand Hyatt San Diego
San Diego, CA



2024 ANNUAL MEETING